AstraZeneca's Heart Drug Trial Fails to Impress, Raises Industry Concerns
By Editor • August 28, 2026 • 1 min read
AstraZeneca announced the disappointing results of a heart disease clinical trial on Friday, revealing that its experimental silencer drug provided no added benefits for patients already on stabilizer medications.
Specifically, those suffering from ATTR-CM did not show improvements, leading to the trial's abrupt failure. This outcome not only affects AstraZeneca and Ionis Pharmaceuticals but also raises questions for competitors like Alnylam Pharmaceuticals and BridgeBio, hinting at the potential superiority of oral stabilizers over injectable silencers.
Source: www.statnews.com
#AstraZeneca #ATTR-CM #clinical trial #heart disease #Ionis Pharmaceuticals
